BioStock: Saniona reaches milestone in SAN711 study

With a proprietary drug discovery platform that has generated over 20 000 ion channel modulators, Saniona has future-proofed its pipeline. From the platform, SAN711 is the most advanced candidate and, today, it was announced that Saniona has initiated the second part of an ongoing Phase 1 study with SAN711.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/02/saniona-reaches-milestone-in-san711-study/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/